DISCLAIMER

The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

 
SUMMARY

This Phase 1a dose‑escalation study evaluated BGB‑A3055, an investigational humanized monoclonal antibody targeting C‑C motif chemokine receptor 8 (CCR8), administered as monotherapy (Arm A) or in combination with tislelizumab (Arm B) in patients with advanced or metastatic solid tumors. The primary endpoint was safety, with secondary endpoints including preliminary antitumor activity assessed by RECIST version 1.1. As of November 19, 2025, 98 patients received treatment (Arm A, n=42; Arm B, n=56), with median follow‑up of 3.9 and 4.7 months, respectively. Decreased neutrophil count (23.8%) in Arm A and pyrexia (23.2%) in Arm B were the most common BGB‑A3055–related treatment-emergent adverse events. Immune‑mediated enterocolitis was the most common serious adverse event. Dose‑limiting toxicities occurred in 1 patient receiving monotherapy and 3 receiving combination therapy, and no treatment-related TEAEs leading to death were reported. The unconfirmed objective response rate was 7.5% in Arm A and 18.2% in Arm B, with disease control rates of 35.0% and 56.4%, respectively.

 
ClinicalTrials.gov ID: NCT05935098